Major association of vitiligo with HLA-A*02: 01 in Japanese

Pigment Cell and Melanoma Research

Volumn 28, Issue 3, 2015, Pages 360-362

  Jin, Ying ^a,b   Hayashi, Masahiro ^a,c   Fain, Pamela R ^a,b   Suzuki, Tamio ^c   Fukai, Kazuyoshi ^d   Oiso, Naoki ^e   Tanemura, Atsushi ^f   Holcomb, Cherie L ^f,g   Rastrou, Melinda ^g   Erlich, Henry A ^g   Spritz, Richard A ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b University of Colorado Denver and Children s Hospital Colorado   (United States)

^c YAMAGATA UNIVERSITY   (Japan)

^d OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g ROCHE MOLECULAR SYSTEMS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A2 ANTIGEN; HLA A2:01 ANTIGEN; UNCLASSIFIED DRUG; HLA-A*02:01 ANTIGEN;

ARTICLE; AUTOIMMUNE DISEASE; CHROMOSOME 6; CONTROLLED STUDY; DNA SEQUENCE; GENE FREQUENCY; GENETIC ASSOCIATION; HAPLOTYPE; HETEROZYGOTE; HLA SYSTEM; HOMOZYGOTE; HUMAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; SINGLE NUCLEOTIDE POLYMORPHISM; VITILIGO; ASIAN CONTINENTAL ANCESTRY GROUP; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; JAPAN;

ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HLA-A2 ANTIGEN; HUMANS; JAPAN; POLYMORPHISM, SINGLE NUCLEOTIDE; VITILIGO;

EID: 84926986133     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12356     Document Type: Article

References (8)

1. de Bakker, P.I., McVean, G., Sabeti, P.C. et al. (2006). A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC. Nat. Genet. 38, 1166-1172.
2. Birlea, S.A., Spritz, R.A., and Norris, D.A. (2012). Vitiligo. In Fitzpatrick's Dermatology in General Medicine, K., Wolff, L.A., Goldsmith, S.I., Katz, B.A., Gilchrest, A.S., Paller, D.J., Leffell, eds. 8th edn. (New York: McGraw-Hill), pp. 792-803.
3. Devlin, B., Roeder, K., and Wasserman, L. (2001). Genomic control, a new approach to genetic-based association studies. Theor. Popul. Biol. 60, 155-166.
4. Jin, Y., Birlea, S.A., Fain, P.R. et al. (2010). Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. N. Engl. J. Med. 362, 1686-1697.
5. Jin, Y., Ferrara, T., Gowan, K. et al. (2012). DNA re-sequencing identifies common variants of TYR (tyrosinase) and HLA-A that together modulate risk of generalized vitiligo via antigenic presentation. J. Invest. Dermatol. 132, 1730-1733.
6. Narita, T., Oiso, N., Fukai, K. et al. (2011). Generalized vitiligo and associated autoimmune diseases in Japanese patients and their families. Allergol. Int. 60, 505-508.
7. Price, A.L., Patterson, N.J., Plenge, R.M. et al. (2006). rincipal components analysis corrects for stratification in genome-wide association studies. Nat. Genet. 38, 904-909.
8. Spritz, R.A. (2013). Modern vitiligo genetics sheds new light on an ancient disease. J. Dermatol. 40, 310-318.